Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11845155 | 0.86 | HTR2A (0.64) | HTR2AHTR2CHRH1PRCPTERT | |
| SCHEMBL11837204 | 0.86 | HTR2A (0.42) | HTR2AHTR2CHRH1PRCPTERT | |
| SCHEMBL10444268 | 0.85 | GRM7 (0.37) | HTR2AHTR2CHRH1MAOB | |
| SCHEMBL10444478 | 0.85 | HTR2B (0.39) | HTR2AHTR2CHRH1TERTMAOB | |
| SCHEMBL11834111 | 0.83 | HTR2A (0.40) | HTR2AHTR2CHRH1TERTMAOB | |
| SCHEMBL10188319 | 0.83 | HTR2A (0.48) | HTR2AHTR2CHRH1PRCPOPRM1 | |
| SCHEMBL10444467 | 0.83 | GRM7 (0.40) | HTR2AHTR2CHRH1 | |
| SCHEMBL10444469 | 0.83 | NR3C2 (0.41) | HTR2AHTR2C | |
| SCHEMBL10444078 | 0.83 | HTR2A (0.41) | HTR2AHTR2CHRH1TERTMAOB | |
| SCHEMBL19334706 | 0.83 | HTR2A (0.36) | HTR2AHTR2CHRH1TERTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2022-11-08 | — | — | US | disclosed |
| US-20210292321-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-09-23 | — | — | US | disclosed |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2020-10-29 | — | — | US | disclosed |
| US-10596171-B2 | Cap-dependent endonuclease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2020-03-24 | — | — | US | disclosed |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190224198-A1 | CAP-DEPENDENT ENDONUCLEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-07-25 | — | — | US | disclosed |
| WO-2019144089-A1 | CAP-DEPENDENT ENDONUCLEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2019-07-25 | — | — | WO | disclosed |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
| US-20160002211-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20150111854-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO (JP) | 2015-04-23 | — | — | US | disclosed |
| US-8987441-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | SHIONOGI & CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150031876-A1 | METHOD FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8927710-B2 | Substituted polycyclic carbamoylpyridone derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-06 | — | — | US | disclosed |
| US-8865907-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | SHIONOGI & CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492352-B2 | Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative | LUC7L2, CXCR6, RRP12 | HTR2A 3531/4885HTR2C 3800/4885HRH1 1152/4885 |
| US-20150111854-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885HTR2C 2588/4885HRH1 2463/4885 |
| US-20190224198-A1 | CAP-DEPENDENT ENDONUCLEASE INHIBITORS | RNGTT, RNASEH1, RNASEL | HTR2A 3203/4885HTR2C 2253/4885HRH1 1019/4885 |
| US-10596171-B2 | Cap-dependent endonuclease inhibitors | RNGTT, RNASEH1, RNASEL | HTR2A 3203/4885HTR2C 2253/4885HRH1 1019/4885 |
| US-20150065485-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | HTR2A 3825/4885HTR2C 3531/4885HRH1 2046/4885 |
| US-20150031876-A1 | METHOD FOR PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTR2A 1536/4885HTR2C 1662/4885HRH1 425/4885 |
| US-20120022251-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTR2A 1427/4885HTR2C 1594/4885HRH1 443/4885 |
| US-20120184734-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE | CNBP, ZC3HAV1, DPP4 | HTR2A 3825/4885HTR2C 3531/4885HRH1 2046/4885 |
| US-20190248785-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885HTR2C 2588/4885HRH1 2463/4885 |
| US-20170349587-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885HTR2C 2588/4885HRH1 2463/4885 |
| US-20130197219-A1 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | PREP, UNG, DPP4 | HTR2A 3244/4885HTR2C 2588/4885HRH1 2463/4885 |
| US-20200339565-A1 | PRODRUG SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | PREP, UNG, DPP4 | HTR2A 3231/4885HTR2C 2630/4885HRH1 2391/4885 |
| US-20210292321-A1 | ARENAVIRUS GROWTH INHIBITOR COMPRISING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE | CCNA1, CDK7, CCR10 | HTR2A 3479/4885HTR2C 3575/4885HRH1 969/4885 |
| US-10202379-B2 | Substituted polycyclic carbamoyl pyridone derivative prodrug | PREP, UNG, DPP4 | HTR2A 3244/4885HTR2C 2588/4885HRH1 2463/4885 |
| US-20160002211-A1 | METHOD OF PRODUCING PYRONE AND PYRIDONE DERIVATIVES | PNPO, PDXK, CYP3A5 | HTR2A 1427/4885HTR2C 1594/4885HRH1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.